KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Novartis Ag (NVS) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to -$6.6 billion.

  • Novartis Ag's Operating Expenses fell 409.9% to -$6.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$24.4 billion, marking a year-over-year decrease of 823.45%. This contributed to the annual value of -$24.4 billion for FY2025, which is 823.45% down from last year.
  • Novartis Ag's Operating Expenses amounted to -$6.6 billion in Q4 2025, which was down 409.9% from -$6.3 billion recorded in Q3 2025.
  • In the past 5 years, Novartis Ag's Operating Expenses registered a high of -$5.3 billion during Q1 2024, and its lowest value of -$7.0 billion during Q3 2023.
  • Its 5-year average for Operating Expenses is -$5.9 billion, with a median of -$5.9 billion in 2021.
  • Its Operating Expenses has fluctuated over the past 5 years, first plummeted by 2807.59% in 2023, then surged by 2123.72% in 2024.
  • Over the past 5 years, Novartis Ag's Operating Expenses (Quarter) stood at -$6.4 billion in 2021, then rose by 15.56% to -$5.4 billion in 2022, then fell by 11.34% to -$6.0 billion in 2023, then decreased by 5.52% to -$6.3 billion in 2024, then decreased by 4.1% to -$6.6 billion in 2025.
  • Its Operating Expenses stands at -$6.6 billion for Q4 2025, versus -$6.3 billion for Q3 2025 and -$6.2 billion for Q2 2025.